List All Chronic Lymphoid Leukemia (CLL) Trials

Chronic Lymphoid Leukemia (CLL)

 

GDC-0853 Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (UW13044)
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Investigator: Stephen Douglas Smith, MD;   Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01991184

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas (13045)
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Recruiting;   Study ID: NCT02061761

Ibrutinib + Rituximab vs. Fludarabine Phosphate, Cyclophosphamide, and Rituximab for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (E1912)
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Investigator: Mazyar Shadman, MD;   Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma;    Status: Recruiting;   Study ID: NCT02048813